Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.
Reference facts
- Also known as
- Viking VK2735
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Dual GLP-1 / GIP receptor agonist comparable in mechanism to Tirzepatide.
- Targets
- GLP-1R, GIPR
- Indications under research or approved
- Obesity
- Regulatory status (reference entry)
- Investigational (Phase 3 VANQUISH for SC; Phase 2 VENTURE for oral)
- Half-life
- ~5 days (subcutaneous)
- Sequence notes
- Dual GLP-1 / GIP receptor agonist available in subcutaneous (weekly) and oral tablet formulations.
- Originator / sponsor
- Viking Therapeutics
- First reported
- 2023
Primary References
Explore research articles about VK2735
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.